<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828957</url>
  </required_header>
  <id_info>
    <org_study_id>MP-CR-009</org_study_id>
    <nct_id>NCT01828957</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants</brief_title>
  <official_title>Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem® Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medipost Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medipost Co Ltd.</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of a single intratracheal
      administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk
      premature infants by comparing Pneumostem-treated group with a control group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of BPD (moderate to severe) or mortality at 36 weeks PMA</measure>
    <time_frame>36 weeks PMA</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of BPD (moderate to severe) or mortality rate at 36 weeks PMA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intubation duration</measure>
    <time_frame>36 weeks PMA</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of BPD</measure>
    <time_frame>28-days since birth</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>28-days since birth, 36 weeks PMA, and termination of the trial</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilator dependence</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CPAP treatment</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postnatal steroid use (%) for the purpose of ventilator weaning</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of oxygen use</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Retinopathy of Prematurity (ROP) of Grade III or more</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of Prematurity (ROP) that require treatment with avastin or laser</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth velocity (Z-score)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay prior to the first discharge from the hospital</measure>
    <time_frame>duration of the hospital stay, an expected average of approximately 3 months since birth</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant laboratory findings</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of pneumothorax that require intubation</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of moderate to severe pulmonary hemorrhage</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intraventricular hemorrhage of grade 3 or more</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Pneumostem®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single intratracheal administration of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumostem®</intervention_name>
    <arm_group_label>Pneumostem®</arm_group_label>
    <other_name>Human umbilical cord blood-derived mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>normal saline</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 5 - 14 days since birth

          -  Fetal gestational age: ≥23 weeks and &lt;29 weeks

          -  Birth weight: ≥500g and ≤1250g

          -  Premature infant of equal to or less than 2 weeks of age who is receiving a
             ventilator therapy at a rate of &gt; 12 breath/min and &gt; 25% oxygen

          -  Patient whose ventilator setting has not been changed and who has shown aggravation
             of the illness within the 24 hours prior to the study enrollment

          -  Patient with a written consent form signed by a legal representative or a parent upon
             explanation of the clinical trial

        Exclusion Criteria:

          -  Patient with  concurrent cyanotic or acyanotic congenital heart diseases, except for
             patent ductus arteriosus

          -  Patient with a concurrent severe lung malformation (i.e. Pulmonary hypoplasia,
             congenital diaphragmatic hernia, congenital cystic lung disease)

          -  Patient with a concurrent severe lung malformation with chromosome anomalies (i.e.
             Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital
             malformation (Hydrocephalus, Encephalocele, etc)

          -  Patient with a concurrent severe congenital infection (i.e. Herpes, Toxoplasmosis,
             Rubella, Syphilis, AIDS, etc)

          -  Patient withCRP &gt; 30 mg/dL; Severe sepsis or shock

          -  Patient who is scheduled for or expected to undergo a surgical procedure 72 hours
             prior to/following the administration of the study drug

          -  Patient who has been administered with a surfactant within the 24 hours prior to the
             administration of the study drug

          -  Patient with severe intracranial hemorrhage ≥ grade 3 or 4

          -  Patient with active pulmonary hemorrhage or active air leak syndrome at the time of
             screening

          -  Patient with a history of participating in other clinical studies

          -  Patient who is allergic to Gentamicin

          -  Patient who is considered inappropriate to participate in the study by the
             investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won-Soon Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ai-Rhan Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neonatology, Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wonil Oh, MD, PhD</last_name>
    <phone>+82-2-3465-6670</phone>
    <email>wioh@medi-post.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Won-Soon Park, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoon-Sil Jang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ai-Rhan Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT01297205?term=medipost&amp;rank=2</url>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 1, 2013</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Umbilical Cord Blood Derived Mesenchymal Stem Cells</keyword>
  <keyword>Bronchopulmonary dysplasia</keyword>
  <keyword>Premature infants</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
